Fresenius Kabi Canada announced the launch of Iodixanol Injection 270 and 320 for both the intravenous and intra-arterial administrations. Iodixanol Injection is a contrast agent with uses in angiocardiography, arteriography, CT scanning of head and body, excretory urography and venography. Health Canada's NOC approval of Iodixanol Injection 270 & 320 was granted on December 17, 2024, and is based on a thorough evaluation of a comprehensive data package demonstrating pharmaceutical equivalence to the reference drug Visipaque®.
With this approval, Fresenius Kabi is building its footprint in the contrast media space in Canada, following recent successful launches of contrast media products in the United States. Expanding a strong presence into the imaging agent space is a substantial cornerstone of Fresenius Kabi's Vision 2026 and the #FutureFresenius strategy.
"Fresenius Kabi's Iodixanol Injection will be the first generic for injectable iodinated contrast media on the market in Canada," said Lee Fulford Sr. Marketing Manager, Specialty Pharma at Fresenius Kabi Canada. "With this launch we are committed to bringing value to Canadians, by lowering the cost as well as adding supply stability to a market that has had devastating shortages historically."
In recent years global shortages of iodinated contrast media have led to Canadian healthcare agencies having to adopt strategies to mitigate shortages including selecting which patients would get contrast and reducing dosages where possible. Iodixanol injection was added in June 2022 to Health Canada's tier 3 drug shortage list. Tier 3 drug shortages are those likely to have the greatest potential impact to the Health Care system.
"We are proud to be introducing an affordable alternative Iodixanol diagnostic option which will strengthen Canada's supply for this critical agent. This launch underscores our commitment to enhancing patient care through accessible therapies," said Martin Willner, General Manager, Fresenius Kabi Canada.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!